Product Information
MYDAYIS ER 50 MG CAPSULE is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $10.7827 per EA under NDC 54092047701. Its NADAC has been published 468 times since Oct 18, 2017.
FDA first approved this application on Jun 20, 2017. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
MYDAYIS ER 50 MG CAPSULE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, and AMPHETAMINE SULFATEStrength
12.5; 12.5; 12.5; 12.5 mg/1; mg/1; mg/1; mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
54092047701
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATEApproval Type
New Drug (NDA)
FDA Application
NDA022063FDA Approved
6/20/2017
TE Code
AB2
On Market Since
6/20/2017
Pharmacological Classes
Price Statistics
The NADAC for MYDAYIS ER 50 MG CAPSULE has been published 468 times since Oct 18, 2017, and over the history we have for it it has risen 24.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.7827 per EA |
|---|---|
| All-time high | $10.8635 (Jan 15, 2025) |
| All-time low | $8.6400 (Oct 18, 2017) |
| 52-week high | $10.8531 |
| 52-week low | $10.7827 |
| Median price | $10.2992 |
| Average price | $9.9686 |
| Largest weekly change | +5.0% (Jan 12, 2022) |
| Weeks tracked | 468 |
| Tracking since | Oct 18, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, and AMPHETAMINE SULFATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Takeda Pharmaceuticals America, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, and AMPHETAMINE SULFATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MYDAYIS ER 50 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for MYDAYIS ER 50 MG CAPSULE, manufactured by Takeda Pharmaceuticals America, Inc., is $10.7827 per EA (NDC 54092047701), effective Sep 30, 2026.
How has the price of MYDAYIS ER 50 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for MYDAYIS ER 50 MG CAPSULE has risen 24.8%. It has been tracked across 468 weekly CMS publications since Oct 18, 2017.
What are the highest and lowest recorded NADAC prices for MYDAYIS ER 50 MG CAPSULE?
Since Oct 18, 2017, the NADAC for MYDAYIS ER 50 MG CAPSULE has ranged from a low of $8.6400 (Oct 18, 2017) to a high of $10.8635 (Jan 15, 2025), with a median of $10.2992 per EA.
Are there cheaper alternatives to MYDAYIS ER 50 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of MYDAYIS ER 50 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures MYDAYIS ER 50 MG CAPSULE?
MYDAYIS ER 50 MG CAPSULE (NDC 54092047701) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.